2篇
您的检索式：作者名="Basma Merhi"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role for urinary biomarkers in diagnosis of acute rejection in the transplanted kidney显示文摘Despite the introduction of potent immunosuppressive medications within recent decades, acute rejection still accounts for up to 12% of all graft losses, and is generally associated with an increased risk of late graft failure. Current detection of acute rejection relies on frequent monitoring of the serum creatinine followed by a diagnostic renal biopsy. This strategy is flawed since an alteration in the serum creatinine is a late clinical event and significant irreversible histologic damage has often already occurred. Furthermore, biopsies are invasive procedures that carry their own inherent risk. The discovery of non-invasive urinary biomarkers to help diagnose acute rejection has been the subject of a significant amount of investigation. We review the literature on urinary biomarkers here, focusing on specific markers perforin and granzyme B m RNAs, FOXP3 m RNA, CXCL9/CXCL10 and mi RNAs. These and other biomarkers are not yet widely used in clinical settings, but our review of the literature suggests that biomarkers may correlate with biopsy findings and provide an important early indicator of rejection, allowing more rapid treatment and better graft survival. | Basma Merhi George Bayliss Reginald Y Gohh | 2015 | World Journal of Transplantation2015，5，4： | 4 |
| 2 | More than skin deep? Potential nicotinamide treatment applications in chronic kidney transplant recipients显示文摘Non-melanoma cutaneous carcinomas, or skin cancers, predominantly squamous cell carcinomas(SCCs), are the most common malignancies occurring in kidney transplant recipients(KTRs). Squamous cell carcinoma risk is dramatically elevated in KTRs, occurring at rates of up 45-250 times those reported in general populations. New non-melanoma skin cancers in KTRs with a prior non-melanoma skin cancer also develop at 3-times the rate reported in non-KTRs with the same clinical history. The unique aggressiveness of SCCs in KTRs increases patient morbidity, due to the high rate of new lesions requiring treatment, frequently surgical excision. Oral nicotinamide shows promise in the chemoprevention of the especially aggressive non-melanoma skin cancers which occur in KTRs. This benefit might be conferred via its inhibition of sirtuin enzymatic pathways. Nicotinamide's concurrent hypophosphatemic effect may also partially ameliorate the disturbed calcium-phosphorus homeostasis in these patients-a putative risk factor for mortality, and graft failure. Conceivably, a phase 3 trial of nicotinamide for the prevention of non-melanoma skin cancers in KTRs, lasting at least 12-mo, could also incorporate imaging and laboratory measures which assess nicotinamide's impact on subclinical cardiovascular and chronic kidney disease risk, and progression. | Andrew G Bostom Basma Merhi Joanna Walker Leslie Robinson-Bostom | 2016 | World Journal of Transplantation2016，6，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员